A larger phase IIb trial of intranasal glutathione (300 mg/dose, three times daily for 3 months, n=45) also showed no significant improvement over placebo (Mischley et al., J Parkinsons Dis, 2017) [52]
We advise against use in patients with active cancer, cardiovascular disease, autoimmune disorders, liver or kidney disease, clotting issues, pregnancy or breastfeeding, or those under age 20
One of our members recently brought up the point about self injection with their MP, who referred the matter to the MHRA
doi: 10.1001/jamanetworkopen.2020.19722 42 MessikaJ.SztrymfB.BertrandF.Billard-PomaresT.BarnaudG.BrangerC.et al
David Sinclairs research on NAD+ and its role in cellular repair, energy production, and healthy aging